Altria said its board approved the multi-phase Optimize & Accelerate initiative on October 30, 2024. It expects at least $600 million in cumulative cost savings over the next 5 years from the initial phases. It said the estimated pre-tax charges are approximately $100 million to $125 million, which it plans to treat as special items.

1. 01

   Altria said its board approved the multi-phase Optimize & Accelerate initiative on October 30, 2024. It expects at least $600 million in cumulative cost savings over the next 5 years from the initial phases. It said the estimated pre-tax charges are approximately $100 million to $125 million, which it plans to treat as special items.

2. 02

   Altria said reported OCI for its oral tobacco products segment for the 9 months ended 2024 decreased $318 million (24.2%). The company cited the non-cash impairment of the Skoal trademark ($354 million) among the factors. Adjusted OCI for the same period increased $36 million (2.7%).

3. 03

   Altria said the FDA issued MGOs for 4 NJOY menthol products on Q2 2024, which obligated it to make cash payments totaling $250 million. It said it made those payments in July 2024. Net cash from operating activities for the 9 months was $5,413 million, down from $6,060 million a year earlier. The company cited a portion of the NJOY contingent payments ($140 million) as one of the factors behind the decline.

4. 04

   Altria received approximately $2.4 billion in pre-tax cash proceeds and paid transaction costs of approximately $62 million from the sale of a portion of its ABI stake in March 2024. It used the proceeds to fund the ASR transactions. The company increased its share repurchase program from $1.0 billion to $3.4 billion and paid $2.4 billion for the repurchase of its common stock in the ASR transactions in the first half of 2024.

Key figures

Quarter ended September 30, 2024

Revenue

$6.3B

Operating income

$3.2B

Net income

$2.3B

EPS

$1.34

Gross profit

$3.8B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.